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Abstract
Neurotrophic factors (NTF) are a subgroup of growth factors that promote survival and differentiation of neurons. Due to
their neuroprotective and neurorestorative properties, their therapeutic potential has been tested in various neurodegen-
erative diseases. Bioavailability of NTFs in the target tissue remains a major challenge for NTF-based therapies. Various
intracerebral delivery approaches, both protein and gene transfer-based, have been tested with varying outcomes. Three
growth factors, glial cell-line derived neurotrophic factor (GDNF), neurturin (NRTN) and platelet-derived growth factor
(PDGF-BB) have been tested in clinical trials in Parkinson’s Disease (PD) during the past 20 years. A new protein can now be
added to this list, as cerebral dopamine neurotrophic factor (CDNF) has recently entered clinical trials. Despite their mis-
leading names, CDNF, together with its closest relative mesencephalic astrocyte-derived neurotrophic factor (MANF), form a
novel family of unconventional NTF that are both structurally and mechanistically distinct from other growth factors. CDNF
and MANF are localized mainly to the lumen of endoplasmic reticulum (ER) and their primary function appears to be
modulation of the unfolded protein response (UPR) pathway. Prolonged ER stress, via the UPR signaling pathways, contributes
to the pathogenesis in a number of chronic degenerative diseases, and is an important target for therapeutic modulation.
Intraputamenally administered recombinant human CDNF has shown robust neurorestorative effects in a number of small and
large animal models of PD, and had a good safety profile in preclinical toxicology studies. Intermittent monthly bilateral
intraputamenal infusions of CDNF are currently being tested in a randomized placebo-controlled phase I–II clinical study in
moderately advanced PD patients. Here, we review the history of growth factor-based clinical trials in PD, and discuss how
CDNF differs from the previously tested growth factors.
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Introduction
Neurotrophic factors (NTF) are small proteins that support
the growth, survival, and differentiation of developing and
mature neurons, and protect them from injury and toxins.
The first NTF to be discovered was nerve growth factor
(NGF)1,2. Since the early research, begun already in the
1940s, a large number of NTFs has been discovered, and
NTFs are today categorized into three main protein families:
neurotrophins [NGF, brain-derived neurotrophic factor
(BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-
4)], the glial cell line-derived neurotrophic factor (GDNF)-
family of ligands [GDNF, neurturin (NRTN), artemin
(ARTN) and persephin (PSPN)], and neuropoietic cytokines
[e.g., ciliary neurotrophic factor (CNTF), interleukin-6 (IL-
6) and cardiotrophin (CT-1)]. An additional distant member
of the GDNF family ligands, a protein called Growth Differ-
entiation Factor 15 (GDF15), which signals via Ret and
binds to the GDNF family receptor alpha-like (GFRAL)
co-receptor, was recently discovered3,4.
Conventional NTF exert their effects on neurons by bind-
ing to receptors, which typically have ligand-binding
domains on the cell surface and cytoplasmic tyrosine kinase
domains, on the plasma membrane of the target cells5–7.
Activation of NTF receptors triggers intracellular signaling
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cascades, in particular phosphatidylinositide-3-kinase (PI3
K)-Akt and Ras-mitogen-activated protein (MAP) kinase
pathways, that promote neuronal survival and stimulate
neurite outgrowth.
A Brief History of Growth Factor Therapy in Parkinson’s
Disease
There has long been interest in the therapeutic use of NTFs,
particularly in neurodegenerative diseases8–10. The blood-
brain barrier (BBB) creates a major challenge in clinical
application of NTFs, as proteins do not pass the BBB, and,
thus, need to be delivered intracranially. Parkinson’s Disease
(PD) is an attractive target for NTF-based therapy as the
disease is characterized predominantly by the degeneration
of a single cell type, the nigrostriatal dopamine neurons, in
an anatomically defined area, representing a discrete thera-
peutic target8. Local delivery of therapeutic proteins with
neuroprotective and neurorestorative properties to the
nigrostriatal pathway, where the cell bodies of dopamine
neurons located at the substantia nigra pars compacta (SNpc)
project their axons to the dorsal striatum, is a feasible ther-
apeutic approach. This is supported also by the widely
accepted view that degeneration of nigrostriatal dopamine
neurons starts with gradual loss of synapses, followed by
axonal degeneration, functional impairment, and eventually
culminating in cell death. The motor symptoms, as well as
some of the non-motor symptoms, of PD are caused by
striatal dopamine deficiency linked to the selective degen-
eration of nigrostriatal dopamine neurons and their fibers,
which occurs in a progressive, slow manner over a long
period of time. Thus, successful protection, regeneration,
and functional recovery of the nigrostriatal pathway is
expected to have disease-modifying effects slowing down
the progression of the disease, which remains a major unmet
need in treatment of PD.
After GDNF had shown robust neurorestorative effects on
motor symptoms and nigrostriatal integrity in both 6-
hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-based animal models of
PD11–14, clinical studies were initiated with high expecta-
tions. In the first attempt to treat human PD patients with
GDNF, monthly intracerebroventricular (i.c.v.) infusions of
the protein were given to 50 PD patients for 8 months in a
phase I–II clinical study. There was no improvement in the
Unified Parkinson’s Disease Rating Scale (UPDRS)15.
Although in a previous non-human primate study, i.c.v.
administration of GDNF resulted in functional recovery11,
it is plausible that, in the larger human brain, the i.c.v. admi-
nistered GDNF protein never reached the nigrostriatal target
neurons in sufficient quantities. In a small open-label phase I
study with five PD patients, continuous intraputamenal infu-
sion of GDNF resulted in progressive and sustained
improvement of motor function and activities of daily liv-
ing16. At 1 year, the off-medication motor sub-score of the
UPDRS was improved by 39% (P < 0.002) and the activities
of daily living sub-score by 61% (P < 0.002). The clinical
improvement was associated with significant increases in
nigrostriatal 18F-dopa uptake in positron emission tomogra-
phy (PET), suggesting neurorestorative effects at the cellular
level. In another open-label phase I study in 10 patients,
unilateral intraputamenal GDNF infusion also demonstrated
>30% improvements in both on- and off-medication UPDRS
total scores at 24 weeks (P < 0.0001 for both on and off, total
UPDRS at 24 weeks vs baseline)17. The clinical effects were
maintained for at least up to 9 months after the end of treat-
ment18. Notably, unilateral administration of GDNF protein
resulted in sustained bilateral effects. These encouraging
open-label trials were followed by a randomized, placebo-
controlled phase II study in 34 patients with continuous
bilateral intraputamenal delivery of GDNF. At 6 months,
there was no statistically significant difference in UPDRS
scores between the placebo and GDNF groups19. Differently
from the previous open-label studies that included intra-
patient dose escalation schemes, all patients in this study
received bilateral continuous intraputamenal infusion of
GDNF at a single dose level throughout the study. In addi-
tion, there were some differences between the types of
in-dwelling brain catheters used in the three studies. Impor-
tantly, the drug delivery system and infusion protocol used in
the phase II study was later tested in Rhesus macaques, and
the results showed point-source concentration and steep con-
centration gradient of GDNF within putamen, suggesting
that the limited volume of distribution of GDNF may have
contributed to the lack of efficacy in this trial20. The authors
of this paper calculated based on their non-human primate
data that the bioavailability of GDNF may have been limited
to only 2–9% of the putamen in human subjects in the phase
II GDNF study. In addition, three of the patients who had
received GDNF in the phase II study were reported to have
developed neutralizing antibodies to GDNF indicating
potential systemic leakage of the drug delivery system. For-
mation of auto-antibodies is a particular concern, as this
would not only limit the efficacy of the protein therapeutic,
but could also interfere with the function of the patient’s
endogenous GDNF. The disappointing results from the
phase II study, together with findings of Purkinje cell loss
in cerebellum in a few GDNF-treated monkeys21, resulted in
discontinuation of the GDNF program by Amgen. Impor-
tantly, case reports of patients who had received GDNF in
the open-label studies showed that clinical improvement
remained for several years after the studies had ended22,23.
A new randomized, placebo-controlled, double-blind
phase II clinical study in 41 PD patients was conducted
recently using intermittent convection-enhanced intraputa-
menal delivery of GDNF protein (ClinicalTrials.gov identi-
fier NCT03652363). In the main study, the patients received
monthly infusions of GDNF, at a single dose of level of 120
mg per putamen, or placebo for 9 months, followed by a 9-
month open-label study where all patients received GDNF at
the same dose level. The improved drug delivery device and
method is expected to provide better coverage of the
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putamen with the active drug infusate, compared with pre-
vious GDNF clinical studies. Importantly, this is the first
clinical trial where GDNF was delivered once a month to
the putamen, whereas all previous trials used continuous
infusion of the trophic factor. In the intention-to-treat popu-
lation at 9 months, the motor UPDRS scores in off-state did
not significantly differ between GDNF and placebo groups
(mean improvements 17.3+17.6% vs 11.8+15.8 from
baseline, P ¼ 0.41, respectively). A post hoc analysis found
nine (43%) patients in the GDNF group but no patients in the
placebo group with a large clinically significant motor
improvement (10 points) in the off state (P ¼ 0.0008).
Importantly, PET imaging showed a significant increase in
18F-dopa uptake throughout the putamen only in the GDNF
group, ranging from 25% (left anterior putamen; P ¼
0.0009) to 100% (both posterior putamina; P < 0.0001)24.
After the 9-month open-label study where all patients
received 120 mg of GDNF per putamen every 4 weeks,
UPDRS in off-state decreased by 26.7+20.7% in patients
on GDNF for 18 months (GDNF/GDNF; n ¼ 21) and
27.6+23.6% in patients on placebo for 9 months followed
by GDNF for 9 months (placebo/GDNF, n ¼ 20; P ¼
0.96)25. No treatment-emergent safety concerns were iden-
tified. These results suggest that intermittent intraputamenal
convection-enhanced delivery of GDNF produced a
putamen-wide tissue engagement effect, overcoming prior
drug delivery limitations. However, in comparison to effec-
tive dose levels of GDNF determined in non-human primate
studies, the dose level of GDNF used in this study was sig-
nificantly lower and suggest that stronger effects could be
seen with optimal dosing level. Moreover, in this study PD
patients with motor symptom duration for 5 years, and
with moderate disease severity in the OFF state (Hoehn and
Yahr stage 2–3 and UPDRS motor score (part III) between
25 and 45) and motor fluctuations were included. GDNF
studies in animal models of PD support the view that GDNF
treatment maybe more effective in earlier stages of disease
when the caudate putamen has more GDNF-responsive
dopaminergic nerve fibers.
An alternative delivery strategy was chosen for NRTN
clinical studies. NRTN is a member of the GDNF family
of ligands (GFLs) shown to provide robust trophic support
for the nigrostriatal dopamine neurons26,27. NRTN signals
through the Ret receptor, as does GDNF, but uses a different
co-receptor (GFRa2 instead of GFRa1; although NRTN can
mediate its signals to Ret also via GFRa1)7. Thus, similar
neurorestorative effects are expected from both GDNF and
NRTN in the injured nigrostriatal pathway. Continuous
expression in the putamen by injection of adeno-associated
virus serotype-2 (AAV2)-neurturin (CERE-120) was used to
overcome the drug delivery issues in previous clinical trials
with NTFs. Although, CERE-120 was intended to provide a
lifetime of NTF support following a single administration,
which may offer some advantages, the risk of this approach
is that in case adverse effects would arise, turning off the
expression of NRTN expression would not be possible. The
CERE-120 construct also included some additional
re-engineering for improving secretion of the mature protein.
Most growth factors are first synthesized as immature pro-
teins containing pre-pro sequences that guide maturation and
secretion of the protein, and which are cleaved off from the
mature growth factor. Since the AAV2 construct with native
NRTN pre-pro sequence resulted in very poor secretion of
NRTN, in the clinically used AAV2 construct it was
replaced with the pre-pro sequence of NGF28.
An open-label phase I study showed good safety and
tolerability for CERE-120 in human PD patients29. In a ran-
domized, sham surgery-controlled phase 2 study, CERE-120
was not superior to sham surgery based on the primary end-
point UPDRS motor score at 12 months30. Interestingly
though, a subset of patients who had a longer blinded
follow-up (for up to 18 months) showed a small but signif-
icant benefit in favor of CERE-120. Also, it should be noted
that separation of the placebo group from the group receiv-
ing CERE-120 was not evident until 6–9 months after dosing
suggesting a long-lasting placebo effect28. Considering the
therapeutic outcome timeline, it is important to note that
after intraparenchymal injection of AAV2 virus vector par-
ticles, protein expression is expected to start by 1 week and
reach steady-state levels by 4 weeks post-injection31. Impor-
tantly, follow-up analysis revealed significant difference in
response of early (5 years after diagnosis) and late-stage
(10 years after diagnosis) PD patients to CERE-120. In
early-stage patients treated with CERE-120, a clear trend
of improvement in motor scores was seen in comparison to
the placebo group. At the same time, no improvement was
observed in late-stage patients who had received CERE-
12032. A post-hoc comparison of CERE-120-treated patients
stratified in two groups (PD diagnosis5 years or10 years
before treatment start) showed a significant difference in
treatment response in terms of UPDRS scores, in favor of
the 5 years since diagnosis group (P ¼ 0.005)33. The fact
that, in patients with disease duration of 10 years before
treatment, the vast majority of nigral dopamine neurons have
already died34 can explain this difference. Since GFLs, and
NTFs in general, can rescue living neurons, the reported lack
of CERE-120 efficacy in clinical trials in late-stage PD
patients was not surprising.
These data also suggest that there may be a delayed ben-
efit with gene transfer-based delivery of NRTN in PD
patients, and, for the first time, showed a disease-
modifying effect in human patients treated with a NTF. Due
to concerns of deficiency in retrograde axonal transport in
advanced PD patients, CERE-120 has been bilaterally admi-
nistered to both putamen and SN in a small safety study,
which supported feasibility of this approach35. The gene
transfer approach is also currently tested for GDNF in an
on-going open-label, single-center phase I dose escalation
study investigating the safety and tolerability of AAV2-
GDNF in advanced PD patients (ClinicalTrials.gov identifier
NCT01621581).
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PDGF-BB is a homodimer of the platelet-derived growth
factor isoform B that has been shown to have restorative
effects in the dopaminergic system in vivo36,37. While the
exact mechanism of the neurorestorative effect of PDGF-BB
remains to be defined, it has been hypothesized that stimula-
tion of periventricular cell proliferation37 and pericyte secre-
tion of neuroregenerative molecules38 would indirectly
mediate these effects. A randomized, placebo-controlled
phase I–IIa clinical study with 2-week continuous i.c.v. infu-
sion of PDGF-BB was conducted in patients with moderate
PD, with a 3-month follow-up period39; i.c.v. PDGF-BB was
safe and well tolerated. While clinical rating scales showed
no change between treatment groups, patients receiving the
highest dose of PDGF-BB showed a significant increase in
dopamine transporter (DAT) ligand binding in PET scans,
compared with placebo patients who showed signal decline
indicating on-going neurodegeneration39. At the end of the
3-month follow-up, there was an improvement in UPDRS
part III motor scores in all cohorts, including the placebo
group. In late 2015, it was announced that clinical develop-
ment of intracerebral PDGF-BB in PD has been discontinued
(Newron S.p.A., press release October 28, 2015). Growth
factor-based clinical trials in PD are summarized in Table 1.
Lessons Learned: from Manufacturing to Clinical Study
Design
There is a large number of potential explanations that may
have contributed to outcome variability between preclinical
and clinical studies using growth factors in treatment of PD,
and several comprehensive reviews have been recently pub-
lished discussing lessons learned from previous NTF clinical
trials32,40,41. Here, we first briefly discuss issues related to
the therapeutic approach, molecular properties of the inves-
tigational drug, manufacturing, preclinical, and clinical
study design considerations, and, in the next section, focus
more specifically on challenges of the intracranial drug
delivery.
From the mechanistic perspective, only two mechanisms
of action have been tested so far in the previous NTF clinical
trials in PD patients. While the exact mechanism behind
PDGF-BB action remains poorly understood, both GDNF
and NRTN promote survival of dopamine neurons and
regeneration of axons via the same pathway involving Ret-
dependent activation of PI3K-Akt and Ras-MAP kinase sig-
naling cascades. New molecular entities and mechanisms of
action should be tested in the future, even in the context of
growth factors. Particularly, as a-synuclein and neuroin-
flammation are important players in PD pathogenesis, they
deserve more attention. In this regard, preclinical testing in
moderate-to-severe lesion models in aged animals (both
rodents and non-human primates) but also in a-synuclein-
based models and in different lines of human dopamine neu-
rons generated from PD patient-derived induced pluripotent
stem (iPS) cells should be performed to build comprehensive
understanding of the therapeutic potential of the
investigational drug. Ideally, patient selection criteria in
clinical studies should reflect those mechanisms that were
effectively targeted in preclinical studies.
Factors likely to affect the efficacy of intracerebral
growth factor therapies include the biological activity and
formulation of the therapeutic, proper construct design of
viral vectors (e.g. pre-pro sequences and promoters deter-
mining expression and secretion efficiency) and compatibil-
ity with the infusion device components, as well as
disease-stage dependent efficiency of retrograde transport
from putamen to SN. One critically important issue is the
source and quality of the recombinant protein. The recombi-
nant human GDNF used in the clinical trials was produced in
Escherichia coli, which has later turned out to be less potent
when compared with GDNF produced in mammalian cells42.
In mammalian cells, GDNF and NRTN are synthesized as
prepro-proteins. In the secretory pathway, GDNF and NRTN
fold along with disulfide bridge formation, GDNF is modi-
fied by N-linked glycosylation at Asn49, and both proteins
undergo proteolytic processing and homodimerization.
GDNF and NRTN are cysteine knot proteins with three intra-
molecular S–S bridges and one S–S bridge holding together
the dimers (Fig 1). After production in E. coli, unglycosylated
GDNF is renatured in vitro. Experimental evidence demon-
strates that both glycosylated and unglycosylated GDNF from
mammalian cells are more stable than the E. coli-produced
chemically renatured GDNF, and that the biological activity
of the E. coli-produced GDNF batches varies42.
Proper folding, post-translational modifications, batch-to-
batch variation and stability of the recombinant protein need
careful attention when manufacturing biologicals for clinical
use. The critical quality attributes of the investigational pro-
tein product need to be carefully monitored, preferably using
orthogonal methods, to ensure consistency in the manufac-
turing process and potency of the investigational protein.
Analytical chemistry methods used for product characteriza-
tion should take into account subtle changes that may occur
to the product between manufacturing batches and during
storage, such as charge, hydrophobicity, glycosylation, dis-
ulfide bridging, terminal modifications, aggregation, and
levels of host cell contaminants (DNA, protein) and other
impurities. Similarly, a panel of binding and potency assays
should provide a comprehensive view on the quality and
stability of the investigational protein.
Compatibility of the investigational protein product with
the drug delivery device components should also be assessed
to verify that biologically active protein is delivered to the
target tissue. Importantly, gene therapy products may also
suffer from problems associated with the product properties.
For example, due to poor expression and secretion of the
protein, the NRTN cDNA in CERE-120 was re-engineered
to contain a pre-pro sequence from human NGF28. Notably,
furin expression in the target cells in the putamen is very
low, likely resulting in poor processing of the pre-pro
sequence47. It is possible that an incompletely processed
recombinant NRTN protein containing the NGF pro
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sequence may induce apoptosis, if secreted48. Thus, verify-
ing that biologically active protein is delivered to the target
cells requires special attention regardless of the delivery
approach. This aspect may have been insufficiently
addressed in many of the previous clinical trials with NTFs.
One alternative strategy that would allow avoiding the
challenges associated with intracranial delivery of biological
drugs is to develop small-molecule mimetics of NTFs that
could be administered peripherally49.
Properly powered, randomized, double-blinded, placebo-
controlled studies should be preferred despite their higher
cost and complexity. Although widely used as a primary
Table 1. Clinical Trials with Growth Factors in Parkinson’s Disease.
Growth factor Delivery Dosing Phase Patients Stage Key findings References
GDNF Lateral ventricle rhGDNF,
monthly
bolus for 8
months
I–II, placebo
controlled
50 H&Y 3–4 (off) No improvement in UPDRS
(off) as drug did not reach
the target, various AEs
(sensory symptoms,
weight loss etc.).
Nutt et al15
Putamen rhGDNF,
continuous
infusion
I, open-label 5 Advanced (>6
years from
diagnosis)
Safe and well-tolerated.
Improvement in motor
symptoms (UPDRS, off),
[18F]dopa uptake
increased near the
catheter tip (PET).
Gill et al16
Putamen
(unilateral)
rhGDNF,
continuous
infusion
I, open-label 10 H&Y 3-4 (off) Improvement in motor
symptoms (UPDRS, off),
effects maintained 9
months after end-of-
treatment.
Slevin et al17,18
Putamen rhGDNF,
continuous
infusion
II, placebo
controlled
34 Advanced (>5
years from
diagnosis)
No improvement in UPDRS
(off), some increase in
[18F]dopa uptake (PET),
development of anti-drug
antibodies.
Lang et al19
Putamen rhGDNF,
CED bolus
for 9þ9
months*
II, placebo
controlled
41 H&Y 3 (off;
>5 years
from
diagnosis)
No improvement in UPDRS
(off), significant increase in
[18F]dopa uptake (PET).
Whone, Luz
et al24;
Whone, Boca
et al25
NCT03652363
Putamen AAV2-GDNF I, open-label 25 H&Y 3-4 (off;
>5 years
from
diagnosis
Study on-going. No results
available yet.
NCT01621581
Neurturin Putamen AAV2-NRTN I, open-label 12 H&Y 3-4 (off;
>6 years
from
diagnosis
Safe and well-tolerated.
Improvement in motor
symptoms (UPDRS, off),
no change in [18F]dopa
uptake (PET).
Marks et al29;
NCT00252850
Putamen AAV2-NRTN II, sham
surgery
controlled
58 Advanced(>5
years from
diagnosis
AAV2-NRTN was not
superior over sham
surgery (UPDRS at
12 months).
Marks et al30;
NCT00400634
Putamen þ SN AAV2-NRTN I, open-label 6 H&Y 2-3 (off;
>4 years
from
diagnosis)
Safe and well-tolerated. Bartus et al35;
NCT00985517
PDGF-BB Lateral ventricle rhPDGF-BB,
continuous
infusion
I–II, placebo
controlled
12 H&Y 2.5-3
(off; >5
years from
diagnosis)
Well-tolerated. No change
in clinical rating scales.
[11C]PE2I DAT binding
increased in right
putamen (PET).
Paul et al39;
NCT02408562
CDNF Putamen rhCDNF,
CED bolus
for 6þ6
months*
I–II, placebo
controlled
18 H&Y 2.5-3
(off; >5
years from
diagnosis)
Study on-going. Topline
results expected in
early 2020.
NCT03295786
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outcome measure in PD clinical studies, UPDRS is not
well-suited for small studies, which is often the case with
intracranially delivered therapeutics. More objective and
practical clinical tools, also capable of assessing daily fluc-
tuation of disease symptoms and non-motor symptoms, for
assessing clinical improvement would be welcome. For
example, digital wearable medical devices, such as the Par-
kinson’s KinetiGraphTM system, allow continuous objective
recording of movement symptoms and provide a valuable
additional tool for assessing clinical outcome measures in
PD studies50,51. Finally, inclusion of PET imaging for
assessment of nigrostriatal pathway integrity is critically
important in clinical studies with neurorestorative therapies.
Development and validation of novel imaging biomarkers
for reliable assessment of a-synuclein pathology and neu-
roinflammation will hopefully support clinical development
of disease-modifying therapies in the future.
Lessons Learned: Challenges of Intracranial Drug
Delivery in Clinical Trials
The clinical studies conducted so far with intracranially
administered growth factors clearly indicate that the drug
delivery method and the neuropharmacokinetic profile of the
therapeutic compound are critical determinants of neurores-
torative effects. Some potential explanations behind differ-
ent results from the open-label and randomized clinical
studies using intraputamenal GDNF infusion have been
published pointing to technical differences in the drug deliv-
ery device and infusion protocol that may have resulted in
poor biodistribution of GDNF in the target tissue20. Another
factor limiting biodistribution of intraparenchymally infused
GDNF and NRTN is associated with their molecular prop-
erties. Both GDNF and NRTN bind strongly to heparan
sulphate-type glycosaminoglycans that are abundant on cell
surfaces and extracellular matrix, which strongly limits
their diffusion in tissue49,52–54. Coinfusion of heparin with
GDNF and NRTN significantly increases their volume of
distribution in animal models55, but this approach is
unlikely to be a clinically useful solution for improving
biodistribution of intraputamenal GDNF and NRTN.
NRTN is a poorly secreted and a poorly soluble protein,
with a particularly high affinity to heparan sulphates.
NRTN variants that were engineered to have reduced
heparin-binding activity showed increased solubility and
stability, as well as broader diffusion in the brain, which
correlated with enhanced regenerative effects in the 6-
OHDA rat model of PD54. Similarly, a novel GDNF variant
with reduced heparin-binding capacity showed improved
brain diffusion52,56. One caveat of this approach is that
deletion of heparin-binding regions from GDNF may have
undesired consequences, such as altered SorLA-mediated
trafficking of GDNF-GFRa1 complex in cells57. Similarly
for gene transfer-based approaches, biodistribution of viral
particles may be limited by affinity to the cell surface or
extracellular components.
Fig 1. Structures of growth factors tested in human Parkinson’s Disease patients. GDNF, NRTN, and PDGF-BB have typical growth factor-
like dimeric structures with predominantly b-sheet secondary structures. CDNF has a distinct two domain, monomeric structure composed
of a-helices only, and contains a CXXCmotif and a C-terminal ER-retention sequence (KTEL). The structures displayed here were retrieved
from PDB and have the following PDB IDs: 1AGQ (GDNF)43, 5NMZ (NRTN)44, 1PDG (PDGF-BB)45, and 4BIT (CDNF)46.
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For growth factor-based therapies, it should be considered
whether continuous presence of the therapeutic is required.
Target engagement in a pulsatile fashion may have benefits
over continuous infusion. For example, ligand-dependent
receptor downregulation and desensitization is a key physio-
logical mechanism that has evolved to protect cells from
overstimulation58. Receptor desensitization that may occur
during continuous administration of growth factors could
decrease responsiveness of the target tissue to the therapeu-
tic. Intermittent delivery may also offer other benefits, such
as reduced risk of loss of protein potency during long incu-
bation period in implanted infusion pumps and reduced risk
of pump malfunction and better monitoring of the infusion
process and parameters. There has been significant progress
in development of drug delivery systems for intermittent
intracranial administration of biopharmaceuticals, lipo-
somes, viruses and cells59,60. Significant progress has been
made in the optimization of the infusion protocol, individual
device components and neurosurgical techniques61,62. This
provides an opportunity to start assessing the pharmacody-
namic properties of neurorestorative biopharmaceuticals
with significantly reduced risk of failed drug delivery to the
target tissue.
Intracranial delivery of therapeutics poses additional risks
for the patient. All studies involving invasive intracranial
procedures have reported adverse effects related to the drug
delivery device or procedure, such as headache, local swel-
ling, and skin reactions. Aside from procedural adverse
effects, mild-to-moderate side effects that were likely asso-
ciated with investigational therapeutic were also reported.
The central side effects of GDNF varied depending on the
route of administration. Appetite suppression, nausea,
vomiting, and weight loss was observed in the GDNF study
using i.c.v. administration15, but not in the GDNF studies
using intraputamenal administration16,17. In the first open-
label GDNF study, mild intermittent Lhermitte’s phenom-
enon, a tingling passing from the neck down the arms and
legs provoked by neck flexion, was reported by patients16. In
addition, high signal intensity in T2 magnetic resonance
images (MRIs) around the tips of catheters was found. While
the cause for these MRI findings remains unclear, the
authors speculated that this could be related to vasogenic
edema or protein buildup near the catheter tip. In addition,
in the second open-label GDNF study some patients experi-
enced sporadic Lhermitte’s phenomenon and similar T2
MRI findings around the catheters were reported17. Overall,
intraputamenally administered GDNF16,17 and i.c.v. admi-
nistered PDGF-BB39 were found to be safe and well-
tolerated. Similarly, in the first growth factor gene therapy
clinical study in PD patients, intraputamenal NRTN gene
therapy was found to be safe and well tolerated29. Out of
12 patients in this study, 3 reported on-medication dyskine-
sias, and 1 patient had hallucinations that were possibly
related to CERE-120. Some patients had asymptomatic
serum antibody responses to AAV2 but no evidence of viral
shedding was found. T2 MRI signal changes seen post-
operatively along the trajectory path of the needle were con-
sidered to be associated with the surgical procedure29.
Clearly, clinical studies completed so far suggest that biggest
safety concerns for clinical use of intracranial growth factor
therapies relate to the drug delivery device and the invasive
implantation procedure.
One common challenge for intracerebral drug therapies is
the stage of patients to be treated. In order for the growth
factor-based therapies to work, some neurons with synaptic
contacts in the caudate putamen should be left to be rescued.
On the other hand, patients at a very early stage of the dis-
ease should not be exposed to the risks of invasive proce-
dures like surgical implantation of a drug delivery device.
Nigral neuron counts and striatal dopamine levels are esti-
mated to be diminished by 50% and 80%, respectively, by
the time of PD diagnosis63,64, and the gradual loss continues
so that the loss of integrity of the nigrostriatal pathway,
based on the rate of dopaminergic marker loss, is nearly
complete by 4–5 years after diagnosis34. Thus, the earlier
the treatment can be started, the better efficacy can be
expected for any NTF-based therapy, as was clearly shown
by the NRTN clinical trials32. However, the risk of misdiag-
nosis, particularly with atypical Parkinsonian syndromes, in
early-stage PD patients is remarkably high65. Thus, careful
consideration, from both clinical and ethical perspectives, is
required.
CDNF is an Unconventional Neurotrophic
Factor
Due to the molecular properties of GDNF and NRTN, which
limit their biodistribution following intraparenchymal infu-
sion, there is interest in novel molecules that have significant
neuroprotective and neurorestorative effects on the nigros-
triatal pathway but biophysical properties better suited for
intracranial delivery. The two most recently discovered pro-
teins with neurotrophic factor-like activity and that have
such potential are cerebral dopamine neurotrophic factor
(CDNF)66 and mesencephalic astrocytic neurotrophic factor
(MANF)67.
Mechanistic Implications from Protein Structure
Although CDNF was originally discovered and described as
a neurotrophic factor, the current view is that CDNF (and
MANF) are structurally (Fig 1) and functionally (Fig 2)
distinct from the classical NTF68. CDNF is a conserved pro-
tein in vertebrates and invertebrates, and shares no signifi-
cant sequence homology to other proteins with the exception
of MANF66. CDNF and MANF are small monomeric pro-
teins with a molecular weight of approximately 18 kDa
(mature proteins 161 and 158 amino acids, respectively) that
are expressed in the central nervous system but also in non-
neuronal tissues. They contain an N-terminal signal peptide
that directs them to the ER. Notably, both CDNF and MANF
also contain a C-terminal KDEL-like ER-retention signal
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that is typically absent in growth factors destined for secre-
tion. Both CDNF and MANF accumulate in the ER lumen in
healthy cells and disruption of the C-terminal ER-retention
signal results in their secretion69–71. Detectable levels of
CDNF and MANF are found in normal human serum, and
MANF also in cerebrospinal fluid (CSF)72. CDNF has two
potential N-glycosylation sites but glycosylation is not
required for neuroprotective activity of the protein66,73. Nei-
ther protein is glycosylated when expressed in mammalian
cell lines.
Although CDNF and MANF share only *60% amino
acid sequence homology, they have highly similar three-
dimensional structures74,46. The structure of CDNF is com-
posed of two independently folded domains connected by a
flexible loop region (Fig 1D). The secondary structure is
predominantly a-helical, with five a-helices in the N-
terminal domain, and three a-helices in the C-terminal
domain. Three disulfide bridges stabilize the N-terminal
domain while the C-terminal CRAC sequence forms an
internal disulfide bridge. This CXXC disulfide bridge is
found both in CDNF and MANF and it is similar to CXXC
motifs found in oxidoreductases and disulfide isomerases75.
Analysis of the C-terminal CXXC motif of MANF did not
find evidence of oxidoreductase activity but showed that the
CXXC motif is essential for the neuroprotective activity of
MANF76,77. Although similar analysis has not been pub-
lished for CDNF, based on the structural and functional
similarities between CDNF and MANF, it would seem rea-
sonable that the CXXC motif would be essential for the
neuroprotective activity of CDNF as well.
Despite extensive research efforts proteinaceous cell sur-
face receptors for CDNF and MANF have not been identi-
fied. Henderson et al suggested that cell surface localized
KDEL receptors, translocated to cell surface in ER-stressed
cells, could mediate cell surface binding of MANF (and
possibly also CDNF)70. It is also possible that lipid-
mediated interactions with the cell surface could play a
role78. The structures of the N-terminal domains of CDNF
and MANF have a typical globular saposin-like architec-
ture74. Saposins are cysteine-rich proteins that interact with
lipids and membranes. Thus, owing to the saposin-like struc-
ture of the N-termini, it seems plausible that lipid-binding
Fig 2. CDNF protects and improves functionality of stressed neurons via multiple mechanisms. (1a) CDNF suppresses chronic ER stress
through modulation of UPR pathways. Global suppression of translation and altered Ca2þ homeostasis are among the consequences of
prolonged ER stress in neurons, both known to impair synaptic function. CDNF helps to finetune UPR signaling towards adaptive stress
signaling, reducing cell death and improving neuronal functionality. (1b) CDNF promotes the activity of Akt/protein kinase B further
supporting neuronal survival. (1c) CDNF interferes with a-synuclein oligomerization and toxicity. (2) Chronic ER stress promotes neuroin-
flammation which exacerbates neuronal dysfunction. CDNF suppresses neuroinflammation by reducing synthesis and secretion of proin-
flammatory cytokines by microglial cells. (3) Exogenously administered CDNF has long-term effects in the brain. These effects are likely
mediated by altered gene transcription.
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could mediate the initial cellular interaction and internaliza-
tion of these unconventional NTF. Supporting this view, bind-
ing to sulfatide, also known as 3-O-sulfogalactosylceramide,
was recently suggested to mediate internalization and cyto-
protective effects of extracellular MANF79. Further lipid
interactomics studies may provide important new information
on the cytoprotective mechanisms of CDNF and MANF.
Endoplasmic Reticulum as the Main Site of Action
Different from classical NTFs, CDNF and MANF can pro-
tect cells as intracellular proteins but have no effects when
added to the media in healthy cultured neurons66,76,77. How-
ever, they have potent neuroprotective effects when infused
to the brain parenchyma of lesioned animals or microin-
jected into lesioned neurons66,76,80,81. Intrastriatally infused
CDNF protein is internalized by cortical and striatal neurons,
primarily by dopamine neurons, and is retrogradely trans-
ported to the substantia nigra81,82. Electron microscopy
showed that CDNF localized to endosomes and multivesicu-
lar bodies in neurons after intraparenchymal infusion. It
remains currently unknown if and how internalized exogen-
ous CDNF is transported to the ER. Notably, the responsive-
ness of cultured cells to extracellular CDNF and MANF can
be increased by exposing the cells to various stressors, such
as MPPþ, rotenone, tunicamycin, and thapsigargin. Thus,
CDNF appears to have potent effects on stressed or injured
neurons but has no or little effect on healthy cells76,81,83.
This is an important property when considering potential
side effects in therapeutic use in humans.
The preferred localization to the ER lumen and regulated
secretion of endogenous CDNF and MANF suggests they
may be involved in regulation of ER function and home-
ostasis, and possibly serving as secreted paracrine regulators
of stress response in specific tissues. A particularly impor-
tant homeostatic cellular signaling system located at the ER
is the unfolded protein response (UPR) pathway84. The ER is
an important stress-sensing and regulating organelle in cells,
and the UPR serves as a dynamic and adaptive signaling
system in the ER helping to restore cellular homeostasis
during ER stress. ER stress has been increasingly recognized
as a general mechanism involved in a broad variety of human
diseases85,86. The pathophysiology of many chronic dis-
eases, in particular neurodegenerative diseases, has been
shown to involve the UPR pathway and chronic ER
stress86–88.
The three main signaling arms of the UPR are triggered in
mammalian cells by activation of PKR-like ER kinase
(PERK), activating transcription factor 6 (ATF6) and
inositol-requiring enzyme 1a (IRE1a) located at the ER
membrane84. As ER stress attenuates general protein trans-
lation, synapses are likely very sensitive to prolonged ER
stress89. Long-lasting forms of synaptic plasticity are highly
dependent on protein synthesis90. Recent evidence suggests
that the UPR and the ER proteostasis network are fundamen-
tally involved in the maintenance of neuronal physiology at
multiple levels of synaptic function and connectivity91. Pro-
longed or severe ER stress can trigger cell death via the pro-
apoptotic mode of UPR92.
In PD, there are multiple lines of evidence linking UPR to
several disease-relevant pathways (reviewed by Mercado
et al93). Post-mortem analysis of PD brain tissue revealed
abnormally phosphorylated PERK, IRE1, and eukaryotic
translation initiation factor 2a (eIF2a) in dopamine neurons
of the SNpc, and activated PERK and IRE1 colocalizing in
neurons with a-synuclein inclusions94–96, which are the main
component of Lewy bodies—a neuropathological hallmark
of PD. Triplication of the a-synuclein-encoding SNCA gene
in iPS cell-derived neurons, mimicking cellular pathology of
early-onset PD, resulted in induction of the IRE1/XBP1 axis
of the UPR and increased expression of pro-apoptotic UPR
target genes CHOP and BIM95. Expression of ER stress-
related proteins, including GRP78/BiP, XBP1, CHOP, and
ATF4, is also increased in the brain of a-synuclein trans-
genic mice, and the presence of toxic a-synuclein oligomers
at the ER correlates with elevated level of ER stress and
faster disease progression in vivo97,98. The ER may serve
as a potential site of accumulation of toxic a-synuclein con-
formers99, and accumulation of misfolded a-synuclein in the
ER has been reported in brain tissue from human PD
patients100. Pathological forms of a-synuclein may induce
ER stress by directly altering the ER proteostasis or indir-
ectly by impairing ER-to-Golgi traffic101 or by altering ER
Ca2þ homeostasis102. On the other hand, ER stress was
shown to promote a-synuclein aggregation providing a feed-
back loop between ER stress and a-synuclein aggrega-
tion103. Mutant forms of a-synuclein (A53 T and A30P),
found in familial forms of PD, were shown to trigger ER
stress also in astrocytes via the PERK-eIF2a pathway result-
ing in reduced GDNF secretion and increased astrocyte
apoptosis104, which likely contributes to PD pathogenesis.
Interestingly, many genes associated with PD can mod-
ulate the function and stress responses of the ER. ER stress
regulates both expression and subcellular distribution of Par-
kin/PARK2105,106. Expression of Parkin-associated endothe-
lin receptor-like receptor Pael-R, a substrate of Parkin
ubiquitin ligase, induces ER stress and neurodegeneration
in the SNpc of mice107. Downregulation of DJ-1/PARK7
enhances the susceptibility of cells to ER stress and cell
death108. Although direct mechanistic evidence is still lack-
ing, dysregulated function of leucine-rich repeat kinase 2
(LRRK2), PTEN-induced kinase 1 (PINK1) and glucocer-
ebrosidase (GBA1) have also been linked to altered ER
stress responses in vivo109–111.
Toxin-based models of PD (MPTP, 6-OHDA, and rote-
none) show prominent activation of the PERK and IRE1a
pathways112,113. Several studies have shown that targeting
the UPR pathway genetically can robustly alter the course of
dopamine neuron loss following 6-OHDA or MPTP lesion-
ing114,115. Moreover, daily administration of GSK2606414,
an orally available PERK inhibitor, to 6-OHDA lesioned
mice for 3 weeks resulted in strong neuroprotection of
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dopamine neurons, increased striatal dopamine levels and
improved motor performance96. Thus, the toxin-based mod-
els of PD are well suited for studying the therapeutic poten-
tial of ER stress modulating compounds. Notably, when
CDNF and GDNF were compared in the 6-OHDA model
of PD, both proteins activated the survival promoting
PI3K-Akt signaling pathway, but only CDNF decreased the
expression level of tested ER stress markers ATF6, GRP78,
and phosphorylation of eIF2a116.
Neuroinflammation—a key component of most if not all
neurodegenerative diseases—is induced by ER stress117,118.
Brain-resident microglia and astrocytes are the main source
of inflammation in diseases affecting the brain. In glial cells,
both PERK-eIF2a and IRE-1a-TRAF2-IKK pathways can
activate NF-kB, a central regulator of multiple aspects of
immune functions119. PERK pathway can also promote
STAT3 signaling via JAK1120 while the IRE1a pathway can
activate both JNK and p38 kinases via ASK1121,122. There
are thus multiple ways ER stress can promote inflammatory
responses in glial cells.
In vitro data shows that CDNF expression is induced by
ER stress in cultured neurons123, and that CDNF expression
improves neuronal viability by upregulating several proteins
involved in UPR signaling, including GRP78, ATF4, ATF6,
and XBP1, while reducing activation of ER stress-responsive
apoptotic proteins, such as CHOP124. Similarly, CDNF
overexpression in cultured astrocytes alleviated ER stress-
induced cell damage and reduced secretion of proinflamma-
tory cytokines125. Moreover, in cultured microglial cells,
CDNF reduces lipopolysaccharide-induced, JNK-mediated
secretion of proinflammatory cytokines PGE2 and IL-
1b126. Transient expression of CDNF in the SN was also
shown to reduce markers of nitrosative stress and level of
IL-6 after 6-OHDA lesioning127, suggesting that alleviation
of neuroinflammation contributes to the therapeutic effects
of CDNF in the toxin-based models of PD.
In the invertebrates Caenorhabditis elegans and Droso-
phila melanogaster, genetic disruption of the single CDNF/
MANF ortholog resulted in degeneration of dopamine neu-
rons linked to dysfunction of the ER and elevated ER stress
level128,129. MANF-deficient mice strikingly develop severe
diabetes due to progressive postnatal apoptosis of pancreatic
b cells associated with chronic UPR activation130. Interest-
ingly, CDNF-deficient mice display an enteric nervous sys-
tem phenotype relevant to gastrointestinal non-motor
symptoms of PD131.
Finally, in a recent study, MANF was shown to bind to
the nucleotide-binding domain of GRP78 and inhibit both
ADP release from GRP78 and ATP binding to GRP78, sug-
gesting that MANF contributes to protein folding homeos-
tasis as a nucleotide exchange inhibitor that stabilizes certain
GRP78-client complexes132. Although a similar interaction
has not been shown for CDNF, it seems plausible that both
CDNF and MANF would be involved in regulation of ER
homeostasis via direct protein–protein interactions with
some of the key molecules in the ER lumen, such as GRP78
chaperone.
Collectively, the structural and mechanistic studies
strongly suggest that CDNF and MANF are primarily ER
lumen-located proteins with potent cytoprotective properties
in multiple cell types and tissues. CDNF and MANF can be
secreted, likely related to cellular stress, and can protect
neighboring cells in a paracrine fashion. The cell-based
mechanistic studies are supported by phenotypes of CDNF
and MANF knockout animals suggesting that these proteins
are intimately linked with the regulation of UPR signaling
and cellular tolerance to ER stress. Despite the in vivo neu-
roprotective properties of CDNF and MANF, their basic
biological properties clearly suggest that they should not
be classified as conventional NTF. They are rather ER-
located proteins with unconventional neurotrophic activities.
Currently available data on cellular mechanisms and path-
ways regulated by CDNF in neuronal and glial cells are
summarized in Fig 2.
Preclinical Pharmacology and Toxicology Studies
Single unilateral intrastriatal injection of CDNF protein in
the rat 6-OHDA model of PD, both before and after lesion-
ing, resulted in robust recovery of motor functions, and
protection and regeneration of tyrosine hydroxylase (TH)-
positive dopamine neurons and their fibers in the nigrostria-
tal pathway66. Similarly, 2-week chronic intrastriatal
infusion of CDNF via implanted osmotic minipumps gradu-
ally normalized the motor behavior of the 6-OHDA lesioned
rats, with prominent regeneration and sprouting of TH-
positive fibers in the nigrostriatal pathway while GDNF in
comparison had only modest effects81. Notably, CDNF
showed a significantly larger volume of diffusion in this
study compared with GDNF. Two studies found that viral
(AAV2) expression of CDNF in the striatum protected from
6-OHDA induced impairment of motor function with partial
protection of TH-positive cells in the SNpc and TH-positive
fibers in the striatum31,133. Another study suggested that
combined nigral delivery of lentiviral CDNF and MANF
provided stronger protection of nigral dopamine neurons and
increased THþ fiber density in striatum compared to indi-
vidual proteins134. However, it is rather difficult to draw
final conclusions from this study, because the biological
activities of the CDNF and MANF proteins produced by the
respective lentiviral vectors, was not reported. Furthermore,
the levels of CDNF and MANF in the midbrain after gene
therapy remained also unclear.
In MPTP-lesioned mice, bilateral striatal CDNF injec-
tions, given either 20 h before or 1 week after MPTP,
improved horizontal and vertical motor behavior and
increased TH-immunoreactivity in the striatum and the num-
ber of TH-positive cells in SNpc83.
As expected, the therapeutic effects of CDNF are depen-
dent on the number of remaining dopamine neurons in the
nigrostriatal pathway. In the 6-OHDA-based major forebrain
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bundle (MFB) lesion model, mimicking late-stage PD-like
loss of nigrostriatal DAergic function, intranigral CDNF
injections had only marginal effect on motor function135.
However, CDNF injection improved the effect of acute sub-
thalamic deep brain stimulation (DBS) on front limb use
asymmetry at 2 and 3 weeks after CDNF injection and
increased the density of striatal TH staining135. This suggests
that CDNF therapy and DBS could have additive therapeutic
effects in PD patients.
Notably, GDNF failed to exert neuroprotection in a
rodent model of PD based on viral vector-expressed a-synu-
clein136,137 despite prominent efficacy in toxin-based mod-
els. In rats, strong overexpression of human a-synuclein was
reported to drastically reduce the amount of Nurr1 and con-
sequently the levels of GDNF receptor Ret protein138. This
study is, however, under debate139. As a-synuclein accumu-
lation is frequently observed in PD patients, it was suggested
that the loss of Ret might partially explain the lack of effi-
cacy of GDNF in the previous clinical trials138. In a recent
study, Su et al evaluated the expression levels of a-synuclein
and GDNF signaling molecules (e.g., Ret and Nurr1) in PD
patient brain samples, a-synuclein transgenic mice, and
AAV-a-synuclein injected rats139. They found that a-synu-
clein mRNA is not increased in sporadic PD and accumula-
tion of a-synuclein does not suppress the expression of
GDNF signaling molecules, including its receptor Ret, in
PD patient samples, and disease models.
Owing to the central role of a-synuclein in the pathogen-
esis of PD, it is important that novel PD therapeutics are
tested also in a-synuclein-based models. CDNF was shown
to protect dopamine neurons from a-synuclein oligomer
toxicity in vitro 46, but efficacy in a-synuclein-based animal
models still remains unpublished.
Non-human primate (NHP) studies have been conducted
with intrastriatally infused CDNF. In 6-OHDA lesioned mar-
moset monkeys (Callithrix jacchus), PET imaging showed a
significant increase of DAT ligand binding activity in
lesioned animals treated with CDNF140. In addition, CDNF
has been tested in a unilateral MPTP model in aged Rhesus
macaques (Macaca mulatta)141.
Neuroprotective and neuroregenerative effects of CDNF
are not specific to the dopaminergic system and various
positive therapeutic outcomes have been reported in other
models of neurodegeneration, including contusion spinal
cord injury in rats142, rat middle cerebral artery occlusion
(MCAO) model of cerebral ischemia123, APP/PS1 mouse
model of Alzheimer’s disease143, and genetic models of
amyotrophic lateral sclerosis (ALS)144.
In a single dose pharmacokinetics study in healthy rats,
CDNF was bilaterally infused into the rat striatum at two
dose levels. The pharmacokinetic profile was similar for
both doses, the tissue half-life of CDNF protein in the stria-
tum being 5.5 h and in the substantia nigra approximately 9
h. In a pilot toxicology study in Rhesus macaques (M.
mulatta), toxicokinetic samples of CSF and plasma were
obtained at different timepoints post-first-intraputamenal
dosing of CDNF. The individual variability was rather large,
with average peak plasma levels at 15 min. At 24 h, the
plasma levels were below the limit of detection in all ani-
mals. The highest peak CSF concentration measured roughly
300-fold the CDNF level in plasma. At 72 h, the CSF levels
were reduced significantly, although still measurable. In the
main, non-human primate toxicology study, a primary peak
of absorption was observed at <0.5 h following the end of
infusion. Following a single infusion, concentrations of
CDNF in CSF were generally only detected 4 h following
the end of infusion, and were generally higher when com-
pared with Cmax in plasma145.
Toxicology studies based on repeated (monthly) bilateral
intraputamenal infusions of CDNF were performed in Rhe-
sus macaques as NHPs are the most relevant species based
on in vivo pharmacologic activity and anatomical compar-
ability with the human brain structure. The toxicology pro-
gram was composed of three studies: a maximum feasible
dose tolerability study (n ¼ 8), a 3-month pilot repeat dose
toxicology study (GLP; n ¼ 8), and a 6-month repeat dose
toxicology study with a 4-month recovery phase (GLP; n ¼
36). Intraputamenal infusion of CDNF to male and female
Rhesus macaques was well-tolerated with no CDNF-related
clinical signs, body weight/food consumption effects, altera-
tions in clinical pathology parameters (haematology, coagu-
lation, clinical chemistry, or urinalysis parameters),
electrocardiogram (ECGs), blood pressure, effects on
ophthalmological or neurological evaluations, gross tissue
evaluations or organ weights, nor were there any macro-
scopic or microscopic changes observed in histopathological
examination (Herantis Pharma Plc, unpublished data). No
specific genotoxicity/mutagenicity, carcinogenicity or
reproductive toxicology studies have been conducted with
intraputamenally infused CDNF. The human equivalent dose
of the highest dose of CDNF in the main toxicology study
has a 68-fold safety factor to the first-in-human dose of 120
mg, and a 7-fold safety factor to the highest clinical dose of
1200 mg used in the phase I–II clinical study.
Phase I–II Clinical Study of Intraputamenal CDNF
in PD
The first-in-human study with CDNF, sponsored by Herantis
Pharma Plc, was started in three centers in Sweden and Fin-
land in late 2017. In this randomized, placebo-controlled,
interventional, multi-center, phase I–II study, 18 patients
with idiopathic moderately advanced PD (bilateral, Hoehn
and Yahr 3, disease duration 5 years) will be enrolled
(ClinicalTrials.gov identifier NCT03295786). Monthly infu-
sions of CDNF at three ascending dose levels will be given
for 6 months in the randomized, placebo-controlled main
study followed by an extension study in which all patients
will receive CDNF. A neurosurgically implanted drug
delivery system essentially similar to the one used in the
Bristol GDNF phase II study will be used for intermittent
intraputamenal delivery of CDNF61,62. The investigational
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medicinal product in this study is recombinant human
CDNF protein manufactured in a mammalian cell line. The
biological activity and stability of the protein and its com-
patibility with the drug delivery device system has been
carefully tested145.
The primary endpoint of the study is safety and tolerabil-
ity of intraputamenal CDNF with a co-primary endpoint
assessing safety and implantation accuracy of the drug deliv-
ery system. Secondary objectives include, e.g., evaluation of
drug effects on PD symptoms by UPDRS (part III), timed up
and go test, activities of daily living (UPDRS part I-IV),
patient home diary, PD Questionnaire-39 and Clinical Glo-
bal Scale (CGI). An important exploratory objective of the
study is assessment of the change in caudate and putamen
DAT availability using PET imaging with [18F]FE-PE2I to
assess the integrity of the nigrostriatal system146,147. Other
exploratory endpoints include serum and CSF levels of total
a-synuclein, oligomeric a-synuclein and serine-129 phos-
phorylated a-synuclein148, the level of distribution of CDNF
in serum and CSF after infusion, and periodical assessment
of motor complications by Parkinson’s KinetiGraphTM
(PKGTM) data logger51.
Future Perspectives
As there is preliminary clinical evidence that growth factor-
based treatments have disease-modifying effects in PD
patients, there is a continued motivation to develop
improved biopharmaceuticals and drug delivery methods
in order to slow down, or even stop, the progression of this
chronic debilitating disease. Development of growth factor-
based therapies for PD has suffered from drug delivery chal-
lenges. Novel drug delivery devices and protocols have been
developed to address these issues. In addition, novel proteins
with neurotrophic activity, such as CDNF, have been discov-
ered and developed to the clinical stage. CDNF has a unique
mode of action (regulation of UPR, prevention of apoptosis,
and reduction of glial secretion of proinflammatory cyto-
kines) targeting preferentially injured cells, which clearly
differentiates it from conventional NTFs. Brain-infused
CDNF also diffuses broadly in the tissue, particularly in
comparison to GDNF and NRTN, which may result in addi-
tional benefits beyond the nigrostriatal pathway, with poten-
tial effects on some of the non-motor symptoms of PD. There
is an indication of disease modification from the NRTN gene
therapy trials, and PET imaging has indicated restorative
effects on the nigrostriatal pathway in humans both with
GDNF and NRTN. These important findings encourage fur-
ther development of disease-modifying therapies—a major
unmet clinical need in PD—based on NTFs and other mole-
cules with neuroprotective and neuroregenerative properties.
For improving translational success of growth factor-
based, potentially disease-modifying therapies in PD, precli-
nical studies should carefully mimic the clinical application,
particularly regarding drug delivery. In addition to toxin-
based models using old animals, a-synuclein-based models,
as well as patient iPS cell-derived human dopamine neurons
should be included in the preclinical program. Previous clin-
ical studies have shown that effective delivery to, and distri-
bution within, the target tissue is essential for clinical
efficacy. The challenge of accessing earlier stage PD
patients with therapeutics that require invasive procedures
has to be resolved. As growth factor-based therapies aim
mostly at protection and functional restoration of the remain-
ing neurons in the nigrostriatal pathway, the stage of patients
enrolled to efficacy studies will be critical. Clearly, the lon-
ger the disease has progressed before the treatment is started
the less neurons there are to protect and recover, and the
lower the chances are for meaningful clinical improvement.
On the other hand, the risk of misdiagnosis with earlier stage
patients and ethical concerns of invasive procedures cannot
be ignored. Development of growth factor-action mimicking
small molecules that are suited for peripheral administration
in earlier stage patients could help to overcome many of the
challenges related to invasive drug delivery.
Improved understanding of disease subtypes and mechan-
isms of disease progression in PD should guide clinical study
designs. As PD is known to be etiologically heterogeneous,
clinical study designs with homogenous patient populations
is expected to increase the odds of success. Properly pow-
ered studies with placebo control groups with delayed start
design should be preferred over small open-label studies.
Surrogate biomarkers, such as PET imaging to assess the
integrity of the nigrostriatal pathway, will play an important
role in establishing clinical proof-of-concept, as the clinical
rating scales are not well suited for smaller trials. Further-
more, progress with biomarker research together with the
advent of wearable digital technologies will provide more
sensitive and more objective assessments and endpoints for
clinical studies testing novel disease-modifying therapies in
PD. Last, but not least, due to the immense complexity of the
human brain, patience and persistence is needed from spon-
sors, patients, investors and other stakeholders in the process
of developing disease-modifying therapies for PD.
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